GLP-1 Medications and Thyroid Cancer Risk: What the Evidence Actually Shows

If you’ve started a GLP-1 medication, or if you’re considering one, you may have noticed a warning on the label — something about thyroid cancer, a condition called MEN2, and medullary thyroid carcinoma. Or maybe you saw the television commercial disclaimer. Or your provider mentioned it, and you walked away more worried than informed.

This article is the deep dive that conversation deserves. The thyroid cancer question with GLP-1 medications is genuinely nuanced — it involves animal data that doesn’t cleanly translate to humans, a biologically important distinction between two very different types of thyroid cancer, and a real contraindication that applies to a specific subset of patients. Getting the details right matters both for patient safety and for avoiding unnecessary anxiety in the vast majority of patients for whom this warning is not meaningfully applicable.

Understanding the FDA boxed warning

All GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound) — carry an FDA boxed warning (the strongest warning the FDA issues) stating that these medications are contraindicated in patients with:

A personal or family history of medullary thyroid carcinoma (MTC)
A diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

This warning came directly from rodent studies conducted during drug development. When rats and mice were given GLP-1 receptor agonists at high doses over extended periods, they developed C-cell hyperplasia — an overgrowth of parafollicular C-cells in the thyroid — and in some cases, thyroid C-cell tumors, which are the precursors of medullary thyroid cancer.

What the warning does NOT say: The FDA boxed warning does not state that GLP-1 medications cause thyroid cancer in humans generally. It does not apply to papillary thyroid cancer, follicular thyroid cancer, or Hürthle cell cancer — the types that account for 95–97% of all thyroid cancers. Understanding this distinction is the most important thing in this entire article.

Papillary vs. medullary: two very different cancers

“Thyroid cancer” describes several biologically distinct diseases that happen to occur in the same organ. They come from different cell types, behave differently, have different prognoses, and — critically — have different relationships with GLP-1 medications.

Differentiated thyroid cancers

Papillary, Follicular & Hürthle Cell

Arise from follicular cells — the cells that make thyroid hormone
Account for 95–97% of all thyroid cancers
Papillary is the most common — over 80% of cases
Generally slow-growing; excellent prognosis, especially when small
FDA boxed warning does not apply to these types
GLP-1 receptors expressed in some PTC cells — significance unclear
Most human studies show no increased risk with GLP-1 use

⚠ The contraindicated type

Medullary Thyroid Carcinoma (MTC)

Arises from parafollicular C-cells — cells that produce calcitonin, not thyroid hormone
Accounts for only 3–4% of all thyroid cancers
Produces calcitonin — a measurable, clinically useful tumor marker
More aggressive than differentiated types; does not respond to radioiodine
This is the cancer that appeared in rodent models of GLP-1 exposure
FDA boxed warning applies here
Can be hereditary — associated with MEN2A, MEN2B, and FMTC syndromes

The reason this distinction matters so much clinically: when a patient hears “thyroid cancer warning” and looks it up, they may find articles about thyroid cancer that are almost entirely discussing papillary thyroid cancer — the common, slow-growing, highly curable form. They may then conclude that their GLP-1 medication is giving them the most common thyroid cancer. That is not what the evidence shows, and unnecessary alarm drives treatment discontinuation in patients who may benefit greatly from these medications.

Why the animal data can’t be directly applied to humans

The C-cell hyperplasia and tumors seen in rodents receiving GLP-1 receptor agonists are a real finding — but the biological mechanism by which they occur in rats and mice does not appear to operate the same way in humans. This is not unusual: many drug effects in rodent models don’t translate to humans, and the FDA is appropriately cautious when any tumor signal appears in preclinical data, even when human translation is uncertain.

The key mechanistic difference: in rodents, GLP-1 receptor agonists stimulate calcitonin secretion from C-cells through a cyclic AMP (cAMP)-dependent pathway. This stimulation appears to drive C-cell proliferation at high, sustained doses. In humans, the GLP-1 receptor is expressed in a much smaller percentage of thyroid C-cells — no more than 30% — and calcitonin secretion in humans is largely independent of GLP-1 receptor activation at clinically relevant concentrations. The threshold for cAMP-driven calcitonin release in human C-cells is substantially higher than what these medications produce.

In plain terms

Rats have far more GLP-1 receptors in their thyroid C-cells than humans do. The drugs activate those receptors in rats and stimulate C-cell growth. In humans, the same receptors are present but at a much lower density, and the mechanism that drives C-cell growth in rats doesn't appear to operate meaningfully in humans at the doses used clinically.

The FDA warning exists because the rodent signal was real and the human evidence at the time of approval was insufficient to definitively rule out risk. That was the appropriate regulatory call. But accumulating human data over more than a decade of GLP-1 use has not confirmed a causal medullary thyroid cancer signal in the general population.

What the human evidence actually shows

95–97%

Of thyroid cancers are differentiated (papillary, follicular, Hürthle cell) — the types for which no increased risk has been demonstrated in most studies

3–4%

Of thyroid cancers are medullary — the type the boxed warning applies to; no confirmed causal signal in human RCT data

Cases of medullary thyroid cancer reported in tirzepatide RCTs across all trial arms, in patients with or without diabetes (SURMOUNT program)

The human evidence picture is complex — different study designs have reached different conclusions — but the overall weight of evidence is substantially more reassuring than the boxed warning alone might suggest:

Randomized controlled trials: No cases of medullary thyroid cancer were reported in the major GLP-1 RCT programs (STEP, LEADER, SURMOUNT). Calcitonin levels showed some elevation with higher doses of tirzepatide compared to placebo, but the clinical significance of this change is unclear and no MTC cases resulted.
Scandinavian cohort study (BMJ, 2024): A large population-based study across Scandinavian countries found no evidence of increased thyroid cancer risk with GLP-1 receptor agonist use.
International multisite cohort study (Thyroid, 2025): No increased risk of thyroid cancer demonstrated in a multinational cohort study using active comparator design.
U.S. retrospective cohort study (Diabetes Care, 2025): Results across U.S. databases were mostly non-significant after proper confounding adjustment; findings were consistent with the Scandinavian data.
French cohort study: This study did find a statistically increased risk (58% increased risk with 1–3 years of exposure), though it is subject to methodological limitations including surveillance bias — patients on GLP-1 medications receive more thyroid monitoring and imaging, which leads to detection of cancers that would otherwise remain undetected or found years later.
Clayman Thyroid Center White Paper: Reviewed human clinical evidence, rodent toxicology, and surgical experience at a high-volume thyroid center and found no convincing evidence that GLP-1 RAs cause papillary, follicular, or Hürthle cell thyroid cancers, and no observed clinical association with MTC presentation patterns.

Surveillance bias is a critical confounder. Patients on GLP-1 medications undergo more thyroid monitoring — more ultrasounds, more blood tests — than patients on other medications. When you look harder, you find more things. An increase in thyroid cancer diagnoses shortly after starting a GLP-1 medication is biologically inconsistent with de novo cancer formation (cancers develop over years to decades) and much more consistent with detecting pre-existing lesions that would otherwise have been found later, or never. This is why short-latency diagnoses don't constitute strong causal evidence.

Who is truly contraindicated

⛔ Contraindicated — do not prescribe

Clear contraindications per FDA labeling

Personal history of medullary thyroid carcinoma (MTC) — at any point in their lifetime
Family history of medullary thyroid carcinoma in a first-degree relative
Diagnosis of Multiple Endocrine Neoplasia type 2A (MEN2A)
Diagnosis of Multiple Endocrine Neoplasia type 2B (MEN2B)
Known RET proto-oncogene mutation associated with hereditary MTC risk (e.g., FMTC)

✓ NOT contraindicated

Common situations that do not trigger the warning

Personal or family history of papillary thyroid cancer — most common type; not subject to the boxed warning
Personal or family history of follicular thyroid cancer
Personal or family history of Hürthle cell (oncocytic) thyroid cancer
History of treated benign thyroid nodules
History of Hashimoto's thyroiditis or autoimmune thyroid disease
Hypothyroidism on levothyroxine — not a contraindication
Elevated TSH without structural thyroid pathology

The most common clinical mistake: Conflating "thyroid cancer history" with the MTC/MEN2 contraindication. A patient who had papillary thyroid cancer treated 10 years ago does not have a contraindication to GLP-1 medications. A patient whose mother had papillary thyroid cancer does not have a contraindication. The contraindication is specific to medullary thyroid carcinoma and MEN2 — full stop.

New thyroid nodules: what to do if one is found

Thyroid nodules are extremely common — present in up to 50–65% of the general adult population when specifically looked for with ultrasound. The vast majority are benign. If a new thyroid nodule is found in a patient on a GLP-1 medication, the clinical approach should be systematic — not panicked, and not dismissive.

Evaluate it appropriately: Any new thyroid nodule meeting size or sonographic risk criteria should be evaluated per standard thyroid nodule guidelines (American Thyroid Association or ACR TI-RADS), regardless of GLP-1 status. GLP-1 use does not change the evaluation algorithm.
Don’t attribute causality prematurely: As discussed above, finding a nodule shortly after starting a GLP-1 medication almost certainly reflects detection of a pre-existing lesion, not a drug-induced new cancer. Thyroid cancers develop over years.
Consider calcitonin: If the nodule has features of concern, or if the patient has any family history of thyroid cancer (of any type), a serum calcitonin level is a simple, inexpensive blood test that can specifically assess whether medullary thyroid carcinoma is a concern. See the section below.
Continue medication in most cases: A newly discovered thyroid nodule that is benign on evaluation is not a reason to stop a GLP-1 medication. If workup is ongoing, a shared decision about temporary hold may be appropriate in some cases — but routine nodule discovery does not mandate medication discontinuation.

The calcitonin blood test — what it is and what it can tell you

Calcitonin is a hormone produced by thyroid parafollicular C-cells — the exact cells that are relevant to medullary thyroid carcinoma. Because MTC arises from these cells, serum calcitonin is a sensitive and specific tumor marker for this cancer. It is measurable with a simple blood draw and can provide meaningful clinical reassurance when a patient has a new nodule or when a provider wants to clarify MTC risk before or during GLP-1 therapy.

Interpreting serum calcitonin in the context of thyroid nodule evaluation

Normal

<10 pg/mL

Makes medullary thyroid carcinoma very unlikely. Provides meaningful reassurance in the setting of a new nodule. Most patients on GLP-1 medications will fall here.

Mildly elevated

10–100 pg/mL

May be non-specific. Many benign causes: C-cell hyperplasia, Hashimoto's thyroiditis, renal insufficiency, smoking, proton pump inhibitor use. Warrants endocrinology referral and repeat testing in most cases.

Significantly elevated

>100 pg/mL

Strongly associated with MTC. Warrants urgent endocrinology referral and further evaluation regardless of GLP-1 status. GLP-1 medication should be held pending workup.

Routine calcitonin screening for all patients starting a GLP-1 medication is not universally recommended by current guidelines — the FDA label does not require it, and the European and American Thyroid Association guidelines differ on this point. However, calcitonin measurement is a reasonable clinical tool in specific situations:

A patient with a new thyroid nodule being evaluated on or before starting a GLP-1 medication
A patient with any personal or family history of thyroid disease of uncertain type, where clarifying MTC risk before prescribing is warranted
A patient reporting new neck symptoms (lump, hoarseness, difficulty swallowing) during GLP-1 therapy
A patient who is anxious about the warning and for whom a normal calcitonin result would provide meaningful reassurance and support medication adherence

What a normal calcitonin tells you: A serum calcitonin below 10 pg/mL makes medullary thyroid carcinoma unlikely — even in the presence of a thyroid nodule — and provides a measurable, evidence-based basis for continuing GLP-1 therapy with confidence. This is a clinically useful conversation to have with anxious patients who have heard the warning and are considering stopping their medication.

MEN2 and family history — what to ask and why it matters

Multiple Endocrine Neoplasia type 2 (MEN2) is a rare hereditary syndrome caused by mutations in the RET proto-oncogene. It is characterized by a near-100% lifetime risk of medullary thyroid carcinoma, along with other endocrine tumors depending on the subtype. Patients with MEN2 are specifically identified in the GLP-1 contraindication because their C-cells are genetically predisposed to malignant transformation — the last thing these patients need is any additional potential stimulus to C-cell activity.

MEN2A — MTC + pheochromocytoma + primary hyperparathyroidism. Most common form (~80%).
MEN2B — MTC + pheochromocytoma + mucosal neuromas + marfanoid habitus. More aggressive; MTC often presents in infancy or early childhood.
Familial medullary thyroid carcinoma (FMTC) — MTC only, without other MEN2 features. Also associated with RET mutations. Also a contraindication.

Most patients with MEN2 already know their diagnosis — it carries significant clinical weight and requires ongoing surveillance and management. However, some patients may have a family history of “thyroid cancer” without knowing the specific subtype. This is where a targeted history question matters before prescribing.

🔍 Family history questions to ask before prescribing

"Has anyone in your immediate family ever been told they had medullary thyroid cancer — specifically medullary, not just thyroid cancer?"
"Has anyone in your family been diagnosed with MEN2 or Multiple Endocrine Neoplasia?"
"Has anyone in your family had a pheochromocytoma (adrenal tumor) combined with thyroid cancer?"
"Were you or any family member ever tested for a RET gene mutation?"
If family thyroid cancer history is confirmed but type is unknown: consider checking calcitonin and/or referring to endocrinology before initiating — clarifying the histologic type is worth the time.

For Providers · Clinical Guidance

Having the thyroid cancer conversation — and documenting it properly

The thyroid cancer boxed warning is one of the most commonly misunderstood aspects of GLP-1 prescribing. Patients encounter it on television commercials, medication guides, and pharmacy printouts — often with no clinical context, and in language that sounds more alarming than the actual risk profile warrants for most patients. As a result, a meaningful proportion of patients either decline therapy out of unfounded fear, or stop a medication that is providing real metabolic benefit based on a misapplied warning.

Your job is to provide accurate, calibrated information — acknowledging the real contraindication for those it applies to, while being clear and direct about who is not at elevated risk and why.

How to frame the conversation

For most patients — no contraindication, starting medication

"I want to make sure you've heard about the thyroid warning on the label and that we've talked through it before you start. This medication carries a warning about a rare type of thyroid cancer called medullary thyroid carcinoma — but I want you to understand who that warning actually applies to. It applies to people who have had that specific type of thyroid cancer, or who have a hereditary condition called MEN2. It does not apply to the general population, and it does not mean the medication causes thyroid cancer in most people. The warning came from animal studies where rats developed thyroid tumors at very high doses — and that biology doesn't translate straightforwardly to humans. Human studies over more than a decade have not confirmed that these medications cause thyroid cancer in the general population. For you specifically, based on your history, this contraindication does not apply."

For a patient with a history of papillary thyroid cancer

"The thyroid warning on this medication specifically applies to a type called medullary thyroid cancer — which is different from the papillary thyroid cancer you were treated for. Papillary thyroid cancer comes from a completely different cell type. The warning doesn't apply to your history, and the evidence doesn't show that these medications adversely affect papillary thyroid cancer. That said, I want us to keep appropriate monitoring in place for your thyroid history, and if anything changes clinically — a new nodule, a change in your labs — we'll evaluate it. But your papillary history is not a contraindication to this medication."

For a patient anxious about the warning who wants reassurance

"I understand the warning is concerning — it's written in very alarming language, and you're right to want to understand it. Here's what I can tell you: the warning exists because in animal studies, high doses of these medications caused thyroid tumors in rats. But the biology in rats is quite different from humans when it comes to the thyroid, and more than a decade of data in hundreds of thousands of humans hasn't confirmed that causal link. That said, I take the warning seriously enough that I've asked you about your family history and personal history of thyroid cancer — and specifically the type called medullary thyroid cancer — before prescribing. If you'd like additional reassurance, we can check a calcitonin level, which is a blood test that can specifically rule out concern for the type of thyroid cancer the warning refers to. A normal result would give us both confidence."

For a patient who IS contraindicated

"I want to talk with you about this before we finalize your plan. You mentioned [family member / personal history] of medullary thyroid cancer — and that's specifically the type that this medication carries a warning about. I'm not comfortable prescribing it for you without more information. I'd like to refer you to endocrinology to discuss this further and make sure we understand your personal risk profile fully. There are other approved medications for obesity that don't carry this specific warning, and I want to make sure we find an approach that's right for you."

What to do before prescribing

Ask specifically about personal and family history of medullary thyroid carcinoma and MEN2 — not just "thyroid cancer" generically
If a family history of thyroid cancer is reported but subtype is unknown, clarify before prescribing or refer to endocrinology for pre-prescribing consultation
Consider baseline calcitonin in patients with any existing thyroid nodules, neck symptoms, or significant patient anxiety about the warning
Counsel the patient on warning signs: new neck lump, hoarseness, difficulty swallowing, persistent neck pain — and have them contact you if any develop
Document the screening conversation explicitly — see checklist below

Calcitonin testing: when to use it in practice

Routine calcitonin before every GLP-1 prescription is not required. But selective use is worth considering. Specific situations that warrant checking calcitonin before initiating or during therapy:

Any patient with a thyroid nodule that has not been fully evaluated
Any patient with a family history of thyroid cancer where the specific subtype isn't confirmed as papillary or follicular
A patient who is significantly anxious about the warning and who would benefit from a measurable, normal result to support adherence
A patient who reports new neck symptoms during treatment — hoarseness, lump, pressure

A normal calcitonin (<10 pg/mL) is clinically meaningful and documents that medullary thyroid cancer is unlikely. It also creates a documented baseline that is useful if the patient develops concerns later in treatment.

Documenting the conversation

Documenting the thyroid cancer screening conversation is both a clinical quality marker and a liability protection. A chart note that simply says "Ozempic prescribed" without evidence of the warning discussion leaves a gap. Here is what to document:

Thyroid cancer risk documentation checklist — GLP-1 prescribing

Personal history of medullary thyroid carcinoma screened: Document explicitly — e.g., "Patient denies personal history of medullary thyroid carcinoma"

Family history of medullary thyroid carcinoma screened: Document explicitly — e.g., "Patient denies family history of medullary thyroid cancer; maternal aunt had papillary thyroid cancer (not a contraindication)"

MEN2 history screened: "Patient denies personal or family history of MEN2 or Multiple Endocrine Neoplasia"

Boxed warning discussed: "Patient counseled on FDA boxed warning for medullary thyroid carcinoma; distinction between MTC and differentiated thyroid cancer explained; patient verbalized understanding"

Warning signs reviewed: "Patient instructed to report new neck lump, hoarseness, difficulty swallowing, or persistent neck pain"

Calcitonin ordered (if applicable): "Baseline serum calcitonin ordered prior to initiation given [patient's existing thyroid nodule / family history of uncertain thyroid cancer subtype / patient request for reassurance]"

Existing thyroid nodules noted (if applicable): Document known nodules, prior workup, current surveillance plan — and note that GLP-1 prescribing does not change the nodule management algorithm

Clinical rationale documented where contraindication was uncertain: If a patient had a family member with unspecified thyroid cancer and you've decided to proceed after clarification — document the reasoning explicitly

The clinical bottom line

The thyroid cancer boxed warning on GLP-1 medications deserves serious attention for the specific patients it applies to — those with personal or family history of medullary thyroid carcinoma or MEN2. For everyone else, the evidence from more than a decade of human clinical use and multiple large epidemiologic studies provides substantial reassurance. The key clinical skills are: asking the right screening questions, distinguishing between cancer subtypes in patient histories, using calcitonin selectively and strategically, and documenting the conversation clearly. Getting this right protects patients, supports informed decision-making, and prevents unnecessary treatment discontinuation in people who stand to benefit significantly from these medications.

📋

Related provider guide

GLP-1 First Visit Counseling Framework

Full first-visit checklist including contraindication screening, labwork guidance, and patient communication framework.

→

🩺

Related provider guide

Managing GLP-1 Side Effects in Clinical Practice

The full clinical management reference — including serious adverse events, dose escalation, and documentation.

→

References and sources

Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–1486. doi:10.1210/en.2009-1272
Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide-1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225. doi:10.1136/bmj-2023-078225
Baxter SM, Lund LC, Andersen JH, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: an international multisite cohort study. Thyroid. 2025;35(1):69–78. doi:10.1089/thy.2024.0387
Morales DR, Bu F, Viernes B, et al. Risk of thyroid tumors with glucagon-like peptide-1 receptor agonists: a retrospective cohort study. Diabetes Care. 2025;48(8):1386. doi:10.2337/dc25-0041
Toro-Tobon D, Singh Ospina N, Brito JP. Thyroid cancer risk with GLP-1 receptor agonists: evidence, knowledge gaps, and the path forward. Thyroid. 2025. doi:10.1089/thy.2024.0690
Feier CVI, Faur AM, Muntean C, et al. Exploring connections between weight-loss medications and thyroid cancer: a look at the FDA Adverse Event Reporting System database. Endocrinol Diabetes Metab. 2025. PMC11889434
Lisco G, De Tullio A, Giagulli VA, et al. Glucagon-like peptide-1 receptor agonists and thyroid cancer: is it the time to be concerned? Front Endocrinol. 2023;14. PMC10563602
Clayman Thyroid Center. White paper: evaluating thyroid cancer risk after GLP-1 receptor agonist administration. 2025. Summarized at CancerNetwork
University of Colorado Cancer Center. Does using GLP-1 drugs like Zepbound or Wegovy increase your risk of thyroid cancer? Interview with Bryan Haugen, MD. October 2025. cuanschutz.edu
Vilsbøll T, et al. Assessment of thyroid cancer risk associated with glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2026. doi:10.1111/dom.70291
FDA. Ozempic (semaglutide) prescribing information — boxed warning. Novo Nordisk. FDA label
Silverii GA, Monami M, Dicembrini I, et al. Glucagon-like peptide-1 receptor agonists and cancer risk: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(1):25–35.